Last reviewed: June 30, 2026 Last updated: June 30, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
The samples were incubated for 1 h at RT, washed three times with TBST, reacted with Supersignal West Pico solution (Pierce) for 5 min, and exposed to X-ray film (Agfa)
But an honest assessment requires nuance
Emerging research suggests that combination therapies, multi-targeted drugs, and personalized interventions hold greater potential in modifying AD progression compared to single-target treatments
Subcutaneous delivery is preferred when targeting systemic gene expression changes, tendon/joint repair, or neuroprotective effects